Loading...
Loading...
J.P. Morgan is out with a research report this morning, where it reiterates its Neutral rating on Accuray
ARAY; it has a $6.00 price target on the stock.
The J.P. Morgan analysts cited the company's recently reported earnings report, which was in-line with the expectations.
With revenues down, low visibility, an improving but still-cautious hospital capex market, and increased competition, the analysts do not see a near-term catalyst for either multiple expansion or an inflection toward profitability and as the stock is most likely to remain range-bound in the near-term.
As for valuation, the analysts noted, “We value ARAY on an EV/CY11E sales basis, and apply a 0.9x multiple (discount to the peer group) to our CY11 sales estimate to arrive at our Dec 2011 price target of $6.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in